despit
avail
antimicrobi
agent
vaccin
communityacquir
pneumonia
remain
seriou
problem
sever
form
tend
occur
young
children
among
elderli
sinc
immun
compet
erod
immatur
immun
senesc
respect
main
etiolog
agent
differ
accord
patient
age
geograph
area
streptococcu
pneumonia
haemophilu
influenza
respiratori
syncyti
viru
rsv
parainfluenza
viru
type
import
pathogen
children
wherea
influenza
virus
lead
caus
fatal
pneumonia
elderli
effect
vaccin
avail
organ
howev
still
mani
agent
vaccin
avail
exist
one
suboptim
tackl
problem
empir
approach
systemat
replac
ration
vaccin
design
facilit
grow
knowledg
field
immunolog
microbi
pathogenesi
host
respons
infect
well
avail
sophist
strategi
antigen
select
potent
immun
modul
effici
antigen
deliveri
system
thu
new
gener
vaccin
improv
safeti
efficaci
profil
compar
old
new
agent
emerg
chapter
overview
provid
current
avail
new
vaccin
concept
mucosa
human
respiratori
tract
repres
primari
target
larg
number
microbi
pathogen
typic
colon
asymptomat
process
result
interplay
bacteri
factor
host
clearanc
mechan
clinic
ill
may
result
either
local
releas
bacteri
toxin
system
dissemin
pathogen
breach
mucos
barrier
cours
respiratori
infect
adapt
immun
respons
could
significantli
impair
might
lead
sever
form
diseas
superinfect
turn
complic
clinic
manag
patient
sever
form
respiratori
infect
tend
occur
young
children
among
elderli
immun
compet
erod
immatur
immunesenesc
respect
addit
patient
immunocompromis
result
diseas
therapeut
intervent
greatest
risk
develop
fatal
infect
despit
avail
new
antimicrobi
effect
vaccin
communityacquir
pneumonia
remain
common
seriou
ill
fact
lead
contributor
nearli
million
death
occur
year
due
respiratori
infect
especi
children
develop
countri
main
caus
agent
pneumonia
differ
accord
patient
age
geograph
area
addit
rel
comprehens
studi
specif
aetiolog
pneumonia
due
overlap
clinic
manifest
differ
syndrom
ii
difficulti
establish
precis
aetiolog
iii
frequent
occurr
coinfect
howev
streptococcu
pneumonia
haemophilu
influenza
respiratori
syncyti
viru
rsv
parainfluenza
viru
type
identifi
main
agent
respons
acut
respiratori
infect
children
wherea
influenza
viru
relat
pneumonia
lead
caus
diseaserel
death
elderli
addit
avail
new
sensit
diagnost
test
contribut
identif
hitherto
unknown
lower
respiratori
pathogen
human
metapneumonoviru
hmpv
novel
coronavirus
caus
sever
acut
respiratori
syndrom
sar
signific
effort
invest
last
two
decad
develop
new
diagnost
tool
elucid
molecular
mechan
microbi
pathogenesi
understand
host
clearanc
mechan
result
improv
knowledg
host
respons
infect
immunopathogenesi
turn
facilit
establish
new
prophylact
therapeut
intervent
howev
despit
accomplish
vaccin
develop
mani
pathogen
vaccin
adequ
therapi
avail
exist
one
suboptim
main
approach
appli
vaccin
develop
radic
chang
recent
year
whole
cell
vaccin
systemat
replac
subunit
vaccin
purifi
antigen
code
gene
exploit
combin
new
adjuv
andor
deliveri
system
result
mani
vaccin
develop
exhibit
consist
improv
stabil
safeti
efficaci
profil
also
amen
mucos
administr
therebi
mimick
natur
infect
influenza
virus
commonli
respons
sever
respiratori
ill
human
follow
influenza
b
popul
suscept
infect
renew
annual
rapid
antigen
variat
viru
antigen
variat
due
accumul
point
mutat
two
major
surfac
glycoprotein
viru
haemagglutinin
ha
neuraminidas
na
lead
antigen
drift
viru
often
leav
current
influenza
vaccin
outdat
ineffect
antigen
shift
also
occur
due
segment
natur
viral
genom
favour
emerg
reassort
strain
entir
glycoprotein
acquir
differ
anim
influenza
viru
type
variat
repres
critic
bottleneck
establish
robust
vaccin
strategi
influenza
fact
influenza
viru
capac
spread
persontoperson
complet
new
glycoprotein
subtyp
suddenli
emerg
worldwid
pandem
outbreak
result
earliest
vaccin
influenza
whole
cell
vaccin
obtain
inactiv
virus
grown
allanto
caviti
embryon
chicken
egg
formalin
contemporari
inactiv
influenza
vaccin
still
produc
embryon
egg
improv
manufactur
result
highli
purifi
lessreactogen
detergentsplit
product
three
viral
strain
select
basi
previou
year
surveil
data
preval
subtyp
therefor
vaccin
composit
may
vari
yeartoyear
vaccin
high
benefit
cost
ratio
sinc
influenzarel
ill
eg
hospit
death
effect
prevent
world
total
vaccin
product
approxim
million
dose
maximum
capac
million
dose
howev
world
health
organ
estim
billion
peopl
high
risk
sever
influenza
outcom
eg
elderli
year
age
infant
health
care
worker
children
adult
underli
cardiopulmonari
diseas
furthermor
global
infrastructur
would
abl
handl
time
manufactur
distribut
vaccin
pandem
outbreak
one
altern
would
lower
quantiti
antigen
per
dose
add
adjuv
vaccin
formul
need
test
clinic
trial
anoth
solut
would
improv
current
vaccin
product
technolog
ie
eggderiv
vaccin
howev
limit
number
egg
produc
viral
strain
emerg
could
easili
adapt
embryon
egg
overcom
problem
sever
pharmaceut
compani
embark
project
develop
vaccin
produc
grow
viru
cell
line
influenza
viru
adapt
grow
varieti
mammalian
cell
line
includ
vero
madindarbi
canin
kidney
mdck
cell
strategi
would
also
improv
possibl
upscal
vaccin
product
face
pandem
spread
altern
would
possibl
develop
vaccin
influenza
viru
avian
strain
use
revers
genet
techniqu
see
advanc
vaccinolog
cold
adapt
found
reliabl
effici
procedur
deriv
live
attenu
viral
vaccin
strain
human
coldadapt
ca
viru
strain
grow
primari
chick
kidney
cell
embryon
egg
howev
exhibit
reduc
replic
process
genet
reassort
transfer
six
intern
gene
stabl
attenu
ca
master
donor
strain
influenza
b
new
prevail
wildtyp
epidem
strain
use
gener
attenu
coldreassort
vaccin
proper
level
attenu
genet
stabil
immunogen
show
low
absent
transmiss
medimmun
wyeth
develop
along
line
trival
live
ca
vaccin
flumist
intranas
spray
deliveri
licens
contrast
parenterallyadminist
vaccin
formul
trigger
immun
respons
resembl
observ
natur
infect
despit
moder
hemagglutinationinhibit
antibodi
titr
observ
vacine
flumist
show
efficaci
period
children
includ
protect
antigen
variant
circul
second
year
ca
vaccin
also
stimul
product
nasal
iga
well
tcell
interferon
respons
cellmedi
immun
viru
matrix
nucleoprotein
antigen
may
favour
viral
clearanc
earli
recoveri
ill
advisori
committe
immun
practic
recommend
use
person
year
age
sinc
sideeffect
observ
young
children
wheez
nasal
congest
data
avail
elderli
despit
remark
genet
stabil
vaccin
kept
thu
new
heat
stabl
deriv
recent
develop
show
good
efficaci
clinic
trial
live
vaccin
base
master
viru
strain
develop
institut
appli
microbiolog
austria
grow
wild
influenza
viru
vero
cell
also
demonstr
safe
welltoler
immunogen
intranas
immun
young
adult
number
subunitor
dnabas
vaccin
also
variou
stage
develop
influenza
vaccin
formul
virosom
commerci
berna
biotech
inflex
v
contain
surfac
spike
three
current
circul
influenza
viru
strain
insert
vesicl
membran
three
correspond
viru
type
detail
see
section
pseudovirus
antigen
deliveri
system
compani
also
develop
virosomebas
nasal
formul
howev
withdrawn
market
due
presenc
sideeffect
ie
bell
palsi
assum
link
presenc
escherichia
coli
heat
labil
toxin
lt
adjuv
two
compani
yeda
bionvax
also
develop
peptidebas
influenza
vaccin
nasal
administr
show
protect
efficaci
human
mice
subunit
vaccin
contain
recombin
ha
protein
produc
use
baculoviru
system
success
test
phase
ii
trial
volunt
epiderm
dnabas
influenza
vaccin
contain
ha
gene
deliv
particlemedi
epiderm
deliveri
also
test
human
powderject
serum
haemagglutinationinhibit
antibodi
respons
observ
volunt
receiv
singl
dose
g
dna
strongest
consist
respons
subject
vaccin
highest
dosag
immun
approach
aim
develop
univers
vaccin
broad
spectrum
protect
activ
differ
influenza
strain
among
use
highli
conserv
transmembran
protein
virion
mention
recombin
particul
vaccin
engin
genet
fuse
copi
hepat
b
core
antigen
hbc
fusion
protein
spontan
assembl
viruslik
particl
vlp
provid
complet
protect
lethal
challeng
influenza
viru
mice
promis
result
also
obtain
vaccin
peptid
conjug
neisseria
meningitidi
outer
membran
protein
complex
ompc
monkey
human
piv
hpiv
consist
four
serotyp
second
lead
caus
bronchiti
pneumonia
infant
vaccin
licens
date
piv
howev
sever
approach
current
investig
initi
attempt
provid
protect
use
vaccin
base
formalininactiv
virus
fail
subsequ
work
demonstr
glycoprotein
haemagglutininneuraminidas
hn
f
respons
viru
attach
fusion
abl
stimul
elicit
neutral
antibodi
anim
howev
poor
immunogen
subject
led
current
favour
approach
base
use
live
attenu
piv
live
attenu
piv
vaccin
develop
human
bovin
strain
amen
deliveri
intranas
rout
candid
vaccin
abl
replic
induc
protect
immun
respons
young
infant
even
presenc
matern
acquir
antibodi
two
main
attenu
strain
studi
detail
one
strain
select
passag
viru
african
green
monkey
cell
low
temperatur
bovin
piv
bpiv
strain
antigen
relat
replic
poorli
human
evalu
phase
iii
trial
seroposit
seroneg
children
young
infant
found
overattenu
seroposit
children
immunogen
seroneg
children
infant
howev
magnitud
antihn
respons
lower
children
receiv
vaccin
prompt
engin
chimer
bovinehuman
candid
eg
hpivnb
strain
human
nucleocapsid
replac
bovin
counterpart
strain
express
f
hn
protein
attenu
chimer
virus
contain
intern
gene
f
hn
gene
either
also
test
hamster
berna
biotech
also
develop
virosom
formul
use
success
approach
influenza
vaccin
formalininactiv
candid
respiratori
syncyti
viru
rsv
test
children
consequ
hospit
vaccine
two
death
moreov
vaccin
children
also
suffer
sever
diseas
subsequ
exposur
viru
compar
unvaccin
control
demonstr
elicit
strong
immun
respons
suffici
confer
protect
diseas
even
lead
immunopatholog
reaction
thu
essenti
stimul
right
type
immun
respons
particular
case
rsv
host
respons
play
import
role
pathogenesi
diseas
therebi
make
develop
prevent
vaccin
extrem
difficult
addit
natur
acquir
immun
rsv
neither
complet
longlast
recurr
infect
often
occur
howev
older
children
adult
usual
protect
suggest
protect
sever
diseas
develop
sever
consecut
infect
passiv
immun
rsvneutral
immun
globulin
also
shown
prevent
rsv
infect
newborn
underli
cardiopulmonari
diseas
demonstr
antibodi
play
major
role
protect
diseas
wherea
tcell
immun
target
intern
viral
protein
appear
contribut
clearanc
although
live
attenu
vaccin
seem
prefer
immun
infant
subunit
vaccin
may
choic
elderli
highrisk
children
pregnant
women
candid
subunit
vaccin
base
purifi
f
protein
demonstr
safe
immunogen
even
pregnanc
matern
immun
use
pfpbase
vaccin
could
interest
strategi
protect
infant
younger
month
age
howev
signific
protect
report
phase
iii
trial
perform
children
year
age
cystic
fibrosi
vaccin
subunit
vaccin
base
formul
base
surfac
glycoprotein
f
g
togeth
virion
matrix
protein
rsva
test
healthi
adult
volunt
presenc
either
alum
polyphosphazen
adjuv
shortliv
neutral
antibodi
respons
rsva
rsvb
detect
vaccine
suggest
annual
boost
need
central
domain
g
protein
rsva
rel
conserv
among
virus
group
b
thu
recombin
vaccin
candid
develop
fuse
domain
albumin
bind
region
streptococc
protein
g
candid
shown
moder
immunogen
adult
human
volunt
clinic
develop
interrupt
due
appear
purpura
vaccine
main
two
difficulti
associ
gener
live
attenu
vaccin
rsv
overor
underattenu
viru
limit
genet
stabil
temperaturesensit
ts
ca
coldpassag
cp
mutant
viral
strain
gener
despit
attenu
shown
adult
seroposit
children
cpt
mutant
still
caus
moder
congest
upper
respiratori
tract
seroneg
infant
month
old
recombin
rsv
vaccin
delet
non
essenti
gene
eg
sh
also
carri
cp
ts
mutat
essenti
gene
current
evalu
recombin
dna
technolog
chimer
virus
engin
contain
gene
surfac
glycoprotein
f
nh
togeth
rsv
glycoprotein
f
g
genet
background
one
candid
found
attenu
abl
induc
elicit
immun
respons
rsv
rhesu
monkey
similarli
genom
engin
express
f
hn
protein
either
nativ
solubl
rsv
f
protein
result
strain
induc
rsv
neutral
antibodi
protect
immun
rsv
challeng
african
green
monkey
need
test
safeti
efficaci
rsv
infant
emerg
diseas
origin
describ
guangdong
provinc
china
even
global
outbreak
sar
control
new
infect
report
person
contact
anim
typic
sarscovlik
viru
transmit
anim
human
howev
certain
condit
viru
evolv
earli
human
sarscov
abil
transmit
anim
human
even
human
human
therebi
lead
local
outbreak
mild
diseas
earli
human
sarscov
select
pressur
human
may
evolv
late
human
sarscov
caus
local
global
outbreak
typic
sar
sar
easili
grown
cell
cultur
thu
urgent
need
vaccin
prevent
natur
occur
epidem
outbreak
also
tool
threat
biolog
weapon
sever
structur
protein
express
sarscov
includ
nucleocapsid
envelop
spike
protein
latter
type
transmembran
glycoprotein
respons
viru
bind
fusion
entri
major
target
neutral
antibodi
extracelullar
domain
protein
consist
two
subunit
subunit
possess
receptorbind
domain
rbd
respons
viral
bind
one
receptor
vectorbas
vaccin
express
protein
well
dna
vaccin
encod
fulllength
protein
assess
preclin
studi
modifi
vaccinia
viru
ankara
mva
code
fulllength
protein
administ
either
intranas
intramuscular
rout
neutral
antibodi
elicit
howev
vaccin
ferret
result
liver
damag
challeng
rais
concern
safeti
approach
vaccin
formul
use
differ
synthet
peptid
encompass
linear
b
cell
epitop
protein
identifi
use
sera
convalesc
patient
stimul
high
antibodi
titr
nevertheless
none
trigger
elicit
neutral
activ
hand
studi
demonstr
although
antibodi
protein
late
sarscov
urbani
strain
exhibit
neutral
activ
also
enhanc
infect
earli
human
sarscov
isol
civet
sarscovlik
virus
deriv
protein
truncat
amino
acid
aa
fail
caus
antibodi
depend
enhanc
infect
retain
abil
induc
neutral
antibodi
find
suggest
elimin
put
heptad
repeat
aa
implic
viral
fusion
might
abrog
stimul
viru
infectionenhanc
antibodi
use
nucleoprotein
coronaviru
dna
vaccin
protocol
also
led
stimul
protect
respons
contrast
protect
achiev
recombin
express
nucleoprotein
alon
togeth
matrix
protein
use
demonstr
select
deliveri
system
immun
strategi
play
critic
role
vaccin
efficaci
human
adenovirus
divid
six
subgroup
af
adenoviru
caus
largescal
epidem
acut
respiratori
diseas
dissemin
especi
favour
condit
person
hous
commun
subgroup
virus
associ
pneumonia
immunocompromis
patient
neutral
antibodi
direct
capsid
hexon
fiber
protein
seem
main
effector
mechan
prevent
reinfect
adenoviru
militari
recruit
usa
administ
entericco
capsul
contain
live
virus
serotyp
viru
attenu
deliv
respiratori
rout
abl
replic
gastrointestin
tract
without
caus
diseas
therebi
stimul
protect
respons
respiratori
tract
vaccin
went
product
outbreak
respiratori
diseas
caus
adenoviru
reemerg
among
militari
recruit
sinc
serotyp
caus
adenoviru
associ
respiratori
diseas
young
children
develop
tetraval
vaccin
similar
mention
might
solv
problem
children
howev
implement
vaccin
live
attenu
adenoviru
care
evalu
sinc
recombin
adenovirus
propos
vaccin
vector
tool
transfer
foreign
gene
gene
therapi
protocol
polysaccharidebas
vaccin
pneumonia
macleod
et
al
report
protect
efficaci
capsular
polysaccharid
ps
vaccin
militari
personnel
outbreak
pneumococc
pneumonia
immun
purifi
ps
show
drastic
reduc
reactogen
comparison
previous
use
inactiv
whole
cell
vaccin
major
breakthrough
term
safeti
also
demonstr
specif
virul
factor
purifi
effect
implement
prevent
infecti
diseas
therebi
pave
road
modern
non
toxoidbas
subunit
vaccin
although
serolog
correl
immun
poorli
defin
typespecif
anticapsular
antibodi
respons
protect
immun
howev
immun
serotyp
specif
render
extrem
difficult
develop
univers
vaccin
part
due
elev
number
serotyp
region
variat
domin
serotyp
lack
updat
seropreval
data
certain
region
problem
partial
solv
use
psbase
polyval
vaccin
current
licens
formul
contain
serotyp
pneumonia
cover
approxim
seriou
pneumococc
diseas
western
industri
countri
rel
good
antibodi
respons
elicit
healthi
adult
week
singl
intramuscular
subcutan
immun
unfortun
poorli
immunogen
children
age
less
year
immun
compromis
individu
eg
aid
patient
elderli
peopl
concomit
diseas
induc
good
immunolog
memori
random
control
trial
healthi
elderli
young
men
also
fail
show
benefici
effect
pneumonia
howev
vaccin
recommend
healthi
peopl
year
age
confer
protect
invas
diseas
psbase
vaccin
also
use
pregnant
women
stimul
product
antibodi
transfer
foetu
via
placenta
newborn
breastfeed
howev
still
matter
controversi
whether
matern
vaccin
inde
protect
newborn
pneumococc
infect
second
gener
psbase
conjug
vaccin
stimul
stronger
antibodi
respons
even
infant
young
children
immun
defici
individu
well
immunolog
memori
vaccin
also
suppress
nasopharyng
carriag
pathogen
reduc
bacteri
transmiss
commun
lead
herd
immun
add
consider
valu
implement
introduct
vaccin
usa
result
dramat
declin
rate
invas
pneumococc
diseas
signific
reduct
incid
rate
among
non
vaccin
individu
also
observ
result
herd
immun
howev
licens
sevenval
vaccin
contain
serotyp
caus
sever
diseas
develop
countri
ie
serotyp
new
conjug
vaccin
includ
serotyp
nineval
vaccin
wyeth
two
vaccin
glaxosmithklin
sanofipasteur
provid
better
serotyp
coverag
new
approach
develop
proteinbas
subunit
vaccin
pneumonia
current
pursu
differ
research
group
expect
enabl
gener
univers
vaccin
confer
protect
immun
larg
number
serotyp
well
avoid
complex
manufactur
conjug
vaccin
differ
pneumococc
candid
antigen
pneumolysin
neuraminidas
autolysin
pneumococc
surfac
protein
pspa
adhesin
psaa
earli
phase
clinic
develop
addit
sever
promis
candid
identifi
current
test
preclin
experiment
model
among
two
iron
uptak
abc
transport
pneumonia
piaa
piua
trigger
protect
immun
invas
pneumococc
diseas
mice
screen
pneumonia
genom
express
librari
sera
convalesc
patient
bacteri
surfac
protein
identifi
eg
promot
elicit
protect
antipneumococc
antibodi
mice
recombin
hybrid
protein
success
test
toddler
elderli
volunt
candid
vaccin
abl
trigger
serotypeindepend
respons
sinc
antigen
common
serotyp
pneumonia
major
obstacl
develop
effect
vaccin
h
influenza
capsular
ps
relat
inher
poor
immunogen
tcellindepend
antigen
antibodi
respons
ps
agerel
extrem
poor
immunogen
infant
first
month
life
unfortun
age
group
exhibit
highest
risk
invas
infect
caus
h
influenza
psbase
vaccin
h
influenza
type
b
hib
licens
unit
state
children
month
old
protect
efficaci
licensur
studi
show
inefficaci
vaccin
infant
also
older
children
problem
solv
gener
conjug
hib
vaccin
end
hib
ps
ie
polyribosylribitol
phosphat
prp
coval
link
immunogen
carrier
protein
therebi
lead
tcelldepend
respons
ps
differ
conjug
hib
vaccin
current
exist
vaccin
hboc
prpt
prpomp
make
use
mutant
diphtheria
toxin
tetanu
toxoid
outer
membran
protein
group
b
n
meningitidi
carrier
respect
trigger
similar
immun
respons
recommend
dose
howev
dynam
elicit
respons
may
vari
efficaci
studi
vaccin
show
confer
protect
mening
also
pneumonia
although
hib
vaccin
highli
effect
cost
still
prohibit
world
poorest
nation
howev
establish
global
allianc
vaccin
immun
gavi
move
consist
ahead
make
also
avail
develop
countri
gavi
approv
establish
hib
initi
support
countri
wish
sustain
hib
vaccin
well
explor
whether
introduct
could
consid
prioriti
near
futur
although
introduct
conjug
ps
vaccin
significantli
decreas
preval
invas
hib
diseas
paediatr
infect
due
non
typeabl
h
influenza
nthi
still
highli
preval
nthi
often
associ
otiti
media
sinus
bronchiti
addit
nthi
import
caus
lower
respiratori
infect
adult
chronic
obstruct
pulmonari
diseas
copd
thu
develop
vaccin
nthi
consid
import
goal
public
health
contrast
hib
vaccin
nonencapsul
nthi
strain
must
direct
altern
virul
factor
lipoprotein
wide
distribut
antigen
conserv
among
h
influenza
strain
also
trigger
elicit
protect
immun
anim
vaccin
mucos
rout
thu
incorpor
vaccin
candid
might
facilit
gener
univers
vaccin
typeabl
non
typeabl
h
influenza
even
age
vaccin
avail
b
pertussi
continu
major
caus
childhood
morbid
mortal
ie
approxim
million
case
death
occur
annual
worldwid
sinc
late
incid
whoop
cough
dramat
decreas
develop
countri
result
widespread
immun
first
vaccin
formul
still
use
consist
prepar
base
kill
b
pertussi
frequent
incid
minor
advers
effect
eg
fever
protract
cri
local
erythemat
reaction
well
concern
rais
report
seriou
neurolog
sideeffect
result
declin
vaccin
accept
use
turn
led
reemerg
whoop
cough
complic
seriou
problem
prompt
develop
new
gener
acellular
vaccin
japan
first
countri
success
introduc
acellular
vaccin
whoop
cough
immunis
programm
lead
consist
reduct
report
sideeffect
mid
major
phase
iii
trial
acellular
vaccin
undertaken
sweden
time
ban
whole
cell
vaccin
result
pertussi
epidem
countri
first
vaccin
trial
contain
chemic
detoxifi
pertussi
toxin
pt
filament
haemagglutinin
fha
detoxifi
pt
alon
result
trial
show
whilst
produc
good
antibodi
respons
vaccin
fail
give
adequ
level
protect
infant
monocompon
vaccin
confer
protect
infect
wherea
use
two
compon
candid
gave
incomplet
protect
infect
result
obtain
japan
sweden
stimul
vaccin
compani
usa
europ
establish
vigor
research
programm
aim
develop
new
gener
acellular
vaccin
higher
efficaci
current
avail
vaccin
incorpor
chemic
genet
inactiv
pt
addit
virul
factor
fha
outer
membran
protein
pertactin
prn
fimbrial
protein
fim
efficaci
studi
second
gener
acellular
vaccin
demonstr
confer
level
protect
equival
whole
cell
vaccin
advent
improv
techniqu
antigen
characteris
introduct
acellular
vaccin
contain
genet
defin
compon
also
result
reduct
lottolot
variat
comparison
convent
whole
cell
vaccin
acellular
formul
origin
introduc
japan
howev
despit
wide
implement
vaccin
campaign
infant
children
diseas
continu
endem
addit
countri
high
vaccin
coverag
observ
consist
increment
case
pertussi
adolesc
adult
patient
transmit
diseas
infant
therebi
repres
primari
reservoir
bacteri
transmiss
cycl
commun
abovement
observ
explain
one
follow
factor
improv
detect
techniqu
ii
major
awar
possibl
bacteria
may
affect
age
group
iii
vaccinedriven
antigen
chang
circul
isol
iv
reduct
vaccin
efficaci
time
context
concern
rais
genet
variat
strain
use
vaccin
prepar
circul
isol
seem
true
sinc
current
use
whole
cell
acellular
vaccin
prepar
strain
isol
mass
vaccin
introduct
show
clear
mismatch
respect
circul
strain
steadi
tendenc
decreas
divers
recent
isol
togeth
clonal
expans
epidem
outbreak
time
least
two
surfac
protein
pt
prn
may
chang
suffici
allow
increas
incid
diseas
unfortun
global
inform
antigen
variat
diseas
adult
adolesc
extrem
limit
thu
despit
widespread
introduct
pertussi
vaccin
essenti
continu
surveil
studi
collect
circul
strain
present
view
success
control
pertussi
commun
may
requir
routin
immun
adolesc
adult
new
acellular
vaccin
perhap
combin
diphtheria
tetanu
toxoid
dtap
intervent
might
help
turn
reduc
burden
diseas
transmiss
infant
chlamydia
pneumonia
intracellular
bacterium
transmit
persontoperson
via
respiratori
droplet
pathogen
common
caus
pneumonia
infect
usual
oligosymptomat
asymptomat
young
age
group
howev
rate
asymptomat
carriag
normal
popul
unknown
also
tremend
gap
understand
host
respons
infect
caus
c
pneumonia
studi
focus
develop
effici
diagnost
method
howev
less
work
done
vaccin
develop
pauciti
knowledg
microbi
compon
may
serv
target
antigen
fact
present
licens
vaccin
c
pneumonia
howev
potenti
differ
antigen
major
assess
experiment
anim
model
nevertheless
mice
vaccin
use
protocol
base
prime
dna
boost
recombin
vlp
show
partial
protect
recent
studi
also
suggest
ctl
respons
play
role
protect
clearanc
anim
immun
minigen
encod
seven
b
restrict
ctl
epitop
fuse
endotheli
reticulumtransloc
signal
show
protect
follow
intranas
challeng
virul
c
pneumonia
current
view
multicompon
vaccin
requir
order
induc
protect
respons
use
promis
approach
revers
vaccinolog
combin
proteom
see
section
revers
vaccinolog
wholegenom
c
pneumonia
screen
search
vaccin
candid
antigen
among
expos
immun
access
surfac
protein
select
candid
express
heterolog
system
use
immun
studi
approxim
protein
abl
trigger
elicit
c
pneumoniaebind
antibodi
test
secondari
screen
six
also
abl
neutral
bacteria
vitro
four
inhibit
system
dissemin
c
pneumonia
hamster
model
moraxella
catarrhali
third
common
bacteri
etiolog
agent
otiti
media
children
furthermor
catarrhali
import
caus
respiratori
infect
patient
copd
thu
differ
studi
carri
character
potenti
protect
antigen
context
two
major
omp
cd
e
identifi
consid
prime
candid
antigen
vaccin
develop
protein
express
surfac
show
high
degre
conserv
among
circul
strain
omp
trigger
elicit
bactericid
antibodi
protect
immun
preclin
model
addit
candid
protein
seem
requir
bacteri
colon
human
upper
respiratori
tract
ironinduc
omp
lbp
ironrepress
omp
conjug
vaccin
base
detoxifi
lipooligosaccharid
also
test
mice
intranas
rout
encourag
result
candid
plan
test
clinic
studi
soon
mycoplasma
commens
microorgan
well
opportunist
pathogen
mycoplasma
pneumonia
one
caus
agent
acut
chronic
human
respiratori
diseas
main
respons
primari
atyp
pneumonia
account
approxim
communityacquir
pneumonia
consider
underreport
pneumoniaeassoci
diseas
part
due
wide
divers
clinic
manifest
difficulti
associ
cultiv
clinic
specimen
lack
adequ
diagnost
tool
vaccin
current
avail
pathogen
howev
studi
conduct
human
volunt
late
demonstr
formalininactiv
whole
cell
vaccin
acellular
extract
abl
confer
moder
protect
immun
pneumonia
unfortun
immun
patholog
reaction
observ
follow
challeng
live
organ
therefor
studi
still
need
understand
underli
mechan
observ
autoimmun
respons
specif
need
elucid
specif
role
play
humor
cellular
respons
protect
pneumonia
pneumonia
one
smallest
selfrepl
prokaryot
pathogen
approxim
kb
complet
genom
sequenc
avail
expect
expand
knowledg
physiolog
virul
properti
agent
well
new
hint
vaccin
develop
previous
unrecogn
bacterium
isol
outbreak
legionnair
diseas
design
legionella
pneumophila
spread
l
pneumophila
increas
due
use
aircondition
humidifi
sinc
infect
occur
inhal
aerosol
contamin
water
sourc
sever
approach
develop
fight
facult
intracellular
pathogen
infect
immun
induc
rapid
increas
antibodi
titr
howev
antibodi
seem
play
signific
role
host
resist
particularli
aerosol
challeng
author
also
suggest
antibodi
promot
bacteri
phagocytosi
therebi
favour
invas
subsequ
intracellular
replic
contrast
cellular
respons
appear
import
protect
differ
vaccin
candid
test
past
heat
acetoneand
formalinkil
l
pneumophila
vaccin
abl
confer
protect
immun
guinea
pig
wherea
anim
immun
l
pneumophila
membran
surviv
aerosol
challeng
virul
bacteria
addit
work
demonstr
also
purifi
antigen
major
secretori
protein
major
cytoplasmat
membran
protein
peptidoglycanassoci
lipoprotein
omp
flagella
confer
protect
challeng
virul
l
pneumophila
final
differ
live
attenu
mutant
l
pneumophila
use
anim
infect
model
promis
result
cystic
fibrosi
cf
patient
particularli
suscept
sever
bacteri
infect
lung
pseudomona
aeruginosa
one
promin
etiolog
agent
thu
signific
effort
invest
develop
vaccin
pathogen
surfac
ps
among
antigen
intens
assess
berna
biotech
develop
octaval
vaccin
eight
preval
serotyp
base
op
conjug
exotoxin
consist
reduct
number
cf
patient
chronic
p
aeruginosa
lung
infect
observ
cohort
receiv
basic
immun
protocol
follow
yearli
booster
period
year
conjug
vaccin
induc
product
specif
igg
antibodi
increas
number
igg
memori
b
cell
still
unclear
cellular
respons
might
contribut
overal
protect
confer
vaccin
howev
strong
prolif
respons
lymphocyt
phenotyp
observ
vaccin
individu
respons
carrier
exotoxin
protein
altern
vaccin
strategi
current
test
clinic
trial
among
formul
base
fusion
protein
outer
membran
protein
f
administ
parenter
mucos
rout
formul
demonstr
safe
volunt
confer
increas
protect
p
aeruginosa
cf
patient
cellsurfac
algin
flagella
compon
type
iii
secret
system
inactiv
toxin
proteas
propos
target
antigen
alreadi
clinic
trial
alon
combin
pasteur
return
summer
holiday
continu
studi
chicken
cholera
inocul
chicken
old
cultur
pasteurella
multocida
left
whole
summer
bench
anim
receiv
prepar
protect
challeng
perform
fresh
isol
thu
pasteur
develop
hypothesi
pathogen
could
attenu
exposur
environment
insult
eg
high
temperatur
oxygen
chemic
strategi
success
extrapol
develop
anthrax
vaccin
livestock
signific
econom
benefit
follow
gener
attenu
vaccin
rabi
import
pathogen
toward
end
nineteenth
centuri
pasteur
approach
attenu
inactiv
pathogen
organ
still
constitut
cornerston
vaccin
technolog
exemplifi
recent
major
achiev
vaccinolog
facilit
technolog
eg
adjuv
deliveri
system
revers
vaccinolog
genet
engin
rather
immunolog
advanc
howev
expect
impress
knowledg
accumul
recent
year
field
immunolog
immun
patholog
microbi
pathogenesi
pave
road
new
golden
era
vaccinolog
knowledg
technolog
enabl
ration
vaccin
design
centuri
pertussi
vaccin
progress
crude
bacteri
prepar
highli
purifi
antigen
use
acellular
vaccin
similar
quantum
jump
technolog
allow
develop
subunit
vaccin
influenza
hib
pneumonia
well
product
antigen
recombin
dna
techniqu
eg
genet
inactiv
pt
despit
fact
techniqu
enabl
product
almost
forese
antigen
identif
suitabl
target
still
remain
main
bottleneck
vaccin
develop
advent
genom
exploit
vaccinolog
field
render
possibl
implement
systemat
holist
approach
screen
identif
prioritis
candid
antigen
new
approach
call
revers
vaccinolog
requir
cultiv
origin
pathogen
therebi
amen
highlypathogen
non
cultur
microorgan
possibl
predict
select
promis
candid
analysi
genom
sequenc
silico
clone
express
heterolog
system
result
protein
use
perform
immunolog
andor
function
studi
select
promis
candid
eg
abl
induc
product
microbicid
neutral
antibodi
capac
confer
protect
immun
flank
studi
usual
carri
molecular
epidemiolog
analysi
assess
degre
conserv
among
circul
strain
transcript
profil
evalu
express
natur
infect
timeconsum
process
highli
express
compon
vitro
cultiv
organ
identifi
one
time
separ
differ
compon
one
disadvantag
revers
vaccinolog
solv
convent
method
usual
requir
year
arriv
clinic
trial
wherea
revers
vaccinolog
reduc
process
approxim
year
revers
vaccinolog
also
allow
identif
hundr
potenti
candid
day
comparison
small
number
antigen
convent
approach
provid
decad
research
moreov
revers
vaccinolog
offer
possibl
select
potenti
candid
independ
express
level
purif
easi
revers
vaccinolog
approach
prove
use
field
viral
bacteri
pathogen
eg
hepat
c
viru
group
b
meningococci
group
b
streptococci
revers
vaccinolog
also
becom
essenti
tool
sever
vaccin
develop
project
agent
caus
communityacquir
pneumonia
eg
c
pneumonia
streptococci
potenti
speed
genomicbas
approach
also
shown
nucleotid
sequenc
coronaviru
caus
sar
made
avail
less
one
month
addit
increas
number
avail
genom
bacteria
virus
would
allow
compar
genom
studi
therebi
provid
hint
conserv
protein
famili
andor
function
domain
would
facilit
gener
vaccin
use
immunogen
cover
multipl
microorgan
despit
incred
potenti
revers
vaccinolog
approach
also
import
limit
tab
among
fact
possibl
identifi
nonprotein
antigen
eg
ps
glycolipid
cornerston
mani
success
vaccin
eg
pneumococc
hib
vaccin
current
avail
influenza
vaccin
see
base
inactiv
virus
recent
attenu
ca
virus
virosom
vaccin
exploit
start
materi
wildtyp
viru
inactiv
attenu
last
approach
consist
coinfect
chicken
egg
new
isol
master
attenu
strain
subsequ
select
reassort
virus
desir
genotypephenotyp
howev
virul
certain
viru
strain
render
difficult
implement
tradit
strategi
use
revers
genet
repres
valid
altern
gener
vaccin
rna
respiratori
virus
influenza
viru
piv
rsv
consist
product
viru
clone
dna
therebi
allow
develop
vaccin
pandem
viral
strain
case
eg
avian
addit
mutagenesi
step
would
requir
attenu
virul
new
ha
na
segment
would
transfer
appropri
influenza
viru
master
strain
adapt
grow
cell
line
final
reassort
viru
antigen
specif
pandem
strain
growth
characterist
master
strain
technolog
would
also
allow
product
influenza
vaccin
cell
cotransfect
plasmid
encod
differ
frag
therefor
complet
genom
insid
cell
viru
produc
assembl
one
main
advantag
plasmid
encod
ha
na
easili
replac
therefor
reassort
select
becom
unnecessari
method
would
consider
reduc
time
vaccin
product
mani
month
week
anoth
advantag
would
simpl
manipul
genom
contain
plasmid
would
enabl
detoxif
specif
virul
factor
similar
approach
implement
virus
rsv
piv
sarscov
howev
intellectu
properti
liabil
issu
still
obstacl
industri
develop
reversegeneticsbas
vaccin
furthermor
sinc
result
virus
consid
genet
modifi
organ
addit
problem
may
aris
regulatori
stand
point
infect
agent
either
limit
mucos
membran
need
transit
across
order
caus
diseas
therefor
highli
desir
elicit
effici
immun
respons
local
site
first
line
defenc
laid
stimul
pathogenspecif
respons
portal
entri
expect
impair
infect
ie
colon
therebi
reduc
risk
transmiss
suscept
host
parenter
administ
vaccin
mainli
stimul
system
respons
wherea
vaccin
given
mucos
rout
mimic
natur
infect
therebi
lead
effici
mucos
system
respons
thu
consider
interest
develop
mucos
vaccin
howev
antigen
administ
rout
usual
poorli
immunogen
differ
strategi
pursu
overcom
bottleneck
among
cite
use
advanc
synthet
deliveri
system
ii
live
attenu
bacteri
viral
vector
iii
bacteri
ghost
iv
pseudovirus
v
mucos
adjuv
advanc
synthet
mucos
deliveri
system
particul
antigen
immunogen
solut
due
vulner
degrad
enzym
extrem
ph
thu
would
help
incorpor
protect
vehicl
often
vehicl
serv
protect
also
enhanc
uptak
promot
target
antigen
present
cell
serv
adjuv
commonli
exploit
deliveri
system
gelatin
capsul
dissolv
alkalin
ph
intestin
stomach
ii
mucoadhes
polym
highli
viscou
inert
ps
iii
eldexom
carboxymethyl
cellulos
use
oral
nasal
vagin
deliveri
iv
lipidbas
structur
entrap
antigen
immun
stimul
complex
iscom
liposom
v
biodegrad
micronanospher
base
biocompat
materi
starch
copolym
lactic
glycol
acid
approach
current
explor
develop
vaccin
agent
caus
communityacquir
pneumonia
encourag
result
obtain
among
other
use
surfac
antigen
pneumonia
encapsul
microspher
iscomadjuv
vaccin
obtain
revers
genet
influenza
viru
preclin
model
attenu
virus
bacteria
use
vaccin
candid
per
se
also
deliveri
system
heterolog
antigen
thu
mani
attenu
microorgan
exploit
scaffold
develop
subunit
vaccin
agent
premis
express
recombin
antigen
increas
pathogen
potenti
human
anim
frequent
exploit
bacteri
vector
attenu
deriv
salmonella
enterica
shigella
spp
bacil
bcg
exampl
vaccin
attenu
salmonella
express
oprfopri
also
shown
abl
confer
protect
p
aeruginosa
murin
experiment
infect
model
addit
also
demonstr
recombin
bcgbase
vaccin
express
pspa
confer
protect
pneumonia
infect
anim
model
use
commens
repres
altern
attenu
organ
eg
lactobacilli
context
demonstr
oral
administr
lactobacillu
express
protein
coronaviru
protect
gastric
infect
thu
approach
also
propos
combat
sar
promis
result
also
obtain
use
x
chlamydia
psittaci
hand
differ
attenu
virus
mva
bovin
attenu
adenoviru
use
deliveri
system
heterolog
antigen
fact
mva
recent
exploit
antigen
sar
associ
coronaviru
altern
approach
use
live
attenu
carrier
given
use
bacteri
ghost
ghost
gener
condit
express
lethal
lysi
gene
e
bacteriophag
gramneg
bacteria
lead
format
transmembran
tunnel
bacteri
cellular
envelop
due
high
intern
osmot
pressur
cytoplasm
content
expel
tunnel
therebi
lead
empti
bacteri
cell
envelop
presenc
envelop
compon
ghost
provid
strong
danger
signal
activ
pattern
recognit
receptor
addit
bacteri
ghost
effici
taken
antigenpres
cell
stimul
matur
activ
bacteri
ghost
retain
morpholog
structur
antigen
featur
cell
wall
use
vaccin
candid
per
se
ghost
also
extern
load
purifi
antigen
altern
ghost
gener
recombin
bacteria
express
heterolog
antigen
henc
avoid
difficulti
associ
purif
step
technolog
also
offer
possibl
manipul
topolog
recombin
antigen
eg
antigen
bound
inner
membran
secret
periplasm
space
associ
surfac
encourag
result
obtain
preclin
model
use
ghost
express
chlamydi
antigen
promis
result
report
use
differ
type
pseudovirus
virosom
viruslik
particl
vlp
nonrepl
virallik
structur
virosom
base
principl
reconstitut
empti
viral
envelop
integr
viral
envelop
protein
liposom
offer
versatil
liposom
term
lipid
composit
advantag
includ
viral
membran
protein
virosom
produc
disassembl
viral
membran
envelop
deterg
viral
nucleocapsid
remov
ultracentrifug
reconstitut
fig
contrast
vlp
exploit
capac
recombin
viral
coat
protein
spontan
selfassembl
therebi
mimick
structur
level
viral
capsid
vlp
isol
protein
express
eukaryot
cell
vitro
assemblag
subunit
produc
heterolog
system
main
advantag
lack
viral
genet
materi
intact
envelop
fact
significantli
immunogen
solubl
protein
use
vaccin
per
se
well
deliveri
system
proteinor
nucleic
acid
base
vaccin
carrier
small
molecul
foreign
antigen
express
surfac
simpli
encapsul
addit
amphiphil
adjuv
incorpor
membran
therebi
offer
advantag
combin
adjuv
antigen
one
entiti
without
coval
attach
pseudovirus
especi
attract
mucos
vaccin
protocol
sinc
offer
opportun
use
natur
rout
transmiss
agent
induct
serum
antibodi
secretori
iga
helper
ctl
respons
protect
mucos
pathogen
challeng
report
studi
anim
human
virosom
gener
use
influenza
viru
retain
membran
fusion
properti
similar
viru
therefor
abl
deliv
materi
cytosol
target
cell
offer
possibl
access
mhc
class
irestrict
pathway
antigen
present
prime
ctl
activ
bacteri
toxin
deriv
among
first
molecul
use
mucos
adjuv
character
presenc
moieti
enzymat
activ
b
moieti
mediat
toxin
bind
target
cell
cholera
toxin
close
relat
escherichia
coli
heatlabil
toxin
show
potent
adjuv
activ
coadministr
differ
antigen
mucos
rout
howev
use
human
hamper
intrins
toxic
thu
mutat
deriv
develop
subunit
modifi
remov
adpribosyl
activ
result
polypeptid
retain
adjuvant
absenc
detect
toxic
howev
addit
studi
demonstr
even
deriv
lead
potenti
sever
sideeffect
retrograd
home
adjuv
antigen
neural
tissu
might
explain
least
part
sideeffect
observ
intranas
vaccin
influenza
virosomesbas
formul
contain
heatlabil
toxin
ie
bell
palsi
turn
led
retract
market
howev
chimer
deriv
lack
target
moieti
neural
tissu
ie
b
subunit
avail
might
allow
exploit
high
potenti
molecul
develop
vaccin
respiratori
pathogen
fact
preclin
studi
provid
proofofconcept
use
deriv
bacteri
toxin
gener
acellular
vaccin
microorgan
pneumonia
h
influenza
bacteri
compon
also
explor
activ
adjuv
monophosphoryl
lipid
retain
much
immun
stimulatori
properti
lp
without
inher
toxic
hand
extracellular
matrix
bind
protein
fibronectin
bind
protein
streptococcu
pyogen
also
exhibit
adjuv
activ
offer
possibl
use
dual
antigenadjuv
moieti
formul
recent
report
also
demonstr
vaccin
formul
contain
adamantylamid
dipeptid
nontox
compound
obtain
link
lalaninedisoglutamin
residu
muramyl
dipeptid
antivir
drug
amantadin
confer
protect
non
typeabl
h
influenza
preclin
model
innat
immun
system
play
critic
earli
role
host
defenc
pathogen
microorgan
recognit
pathogenassoci
molecular
pattern
achiev
stimul
patternrecognit
receptor
prr
sens
broad
rang
exogen
endogen
danger
signal
tolllik
receptor
tlr
repres
bestcharacter
famili
prr
natur
synthet
tlr
agonist
use
immun
modul
optim
respons
vaccin
sinc
identif
mani
mammalian
tlr
homologu
identifi
ie
human
mice
tlr
member
bind
specif
differ
ligand
tab
alon
combin
eg
heterodim
form
either
exampl
tlr
agonist
bacteri
dna
vertebr
dna
synthet
oligodeoxynucleotid
contain
unmethyl
cpg
motif
act
therebi
induc
strong
respons
activ
dendrit
cell
cpg
motif
success
use
adjuv
preclin
studi
differ
candid
vaccin
agent
caus
communityacquir
pneumonia
anoth
import
adjuv
tlrbind
capac
mycoplasmaderiv
macrophageactiv
lipopeptid
act
level
tlr
heterodim
promot
global
activ
cell
innat
adapt
immun
system
macrophag
dc
tand
blymphocyt
coadminist
antigen
either
parenter
mucos
rout
promot
elicit
humor
cellular
respons
system
mucos
level
preclin
studi
suggest
could
exploit
vaccin
formul
sarsassoci
coronaviru
catarrhali
influenza
viru
among
other
unpublish
data
dna
vaccin
offer
advantag
normal
antigen
vaccin
fact
necessari
express
antigen
contrast
biosynthet
machineri
present
cell
vaccine
take
care
work
furthermor
sinc
eukaryot
cell
charg
protein
synthesi
glycosyl
fold
optim
howev
largescal
purif
dna
might
associ
high
cost
solv
use
attenu
inactiv
bacteria
virus
deliveri
system
approach
also
lead
enhanc
induct
antibodi
otherwis
poor
use
convent
nake
dna
vaccin
recent
demonstr
bacteri
ghost
also
exploit
deliveri
system
dna
vaccin
vivo
ex
vivo
applic
potenti
approach
demonstr
fact
possibl
optim
perform
broad
rang
manipul
choic
optim
promot
ii
use
codon
optim
gene
express
mammalian
cell
iii
addit
nuclear
local
signal
ubiquitin
signal
improv
express
process
iv
codeliveri
dna
construct
code
immun
modulatori
molecul
addit
presenc
immun
stimulatori
cpg
motif
dna
vaccin
construct
builtin
adjuv
properti
vaccin
approach
particularli
suit
stimul
cellular
immun
respons
interestingli
sever
report
suggest
dna
vaccin
may
repres
valid
altern
prime
neonat
immun
system
even
presenc
passiv
transfer
matern
antibodi
fact
promis
result
also
obtain
preclin
model
communityacquir
pneumonia
influenza
pneumonia
furthermor
dna
code
vaccin
antigen
appear
induc
excel
immunolog
memori
reawaken
later
immun
exposur
pathogen
knowledg
gener
sever
basic
disciplin
immunolog
microbi
pathogenesi
allow
identif
critic
bottleneck
establish
success
vaccin
strategi
expect
come
year
develop
custom
approach
address
order
stimul
effici
protect
infect
agent
specif
clinic
set
ie
newborn
age
individu
immunocompromis
patient
import
immunolog
memori
b
lymphocyt
differenti
plasma
cell
produc
antigenspecif
igg
antibodi
bonemarrow
bm
plasma
cell
short
life
therefor
bm
reservoir
need
replenish
stimul
memori
b
cell
maxim
life
span
bm
plasma
cell
still
debat
factor
identifi
control
differenti
antigenspecif
b
cell
toward
shortor
longlif
plasma
cell
memori
b
cell
besid
requir
cell
natur
antigen
dose
also
import
higher
antigen
dose
well
rapid
vaccin
schedul
close
space
vaccin
dose
tend
favour
rapid
induct
shortterm
effector
wherea
lower
dose
antigen
preferenti
support
induct
immun
memori
demonstr
neonat
vaccin
prime
infant
boost
might
effect
even
pathogen
exposur
occur
earli
life
children
vaccineinduc
hib
antibodi
titr
fallen
undetect
level
memori
readili
demonstr
howev
immun
memori
per
se
enough
protect
pathogen
requir
high
level
neutral
antibodi
delay
memori
bcell
reactiv
differenti
may
limit
abil
interrupt
pathogen
invas
therefor
import
establish
vaccin
protocol
popul
boost
differ
age
order
maintain
requir
level
antibodi
particularli
import
diseas
antibodi
play
central
role
microbi
clearanc
toxin
neutral
particular
case
communityacquir
pneumonia
consid
age
individu
neglect
mani
vaccin
program
howev
strategi
propos
elderli
would
differ
use
small
children
sinc
main
factor
affect
vaccin
efficaci
immun
senesc
immatur
respect
attempt
give
ration
solut
issu
discuss
next
section
immun
system
children
immun
respons
bacteri
viral
antigen
usual
increas
age
stepwis
manner
prompt
immun
birth
requir
induc
activ
immun
diseas
may
occur
earli
life
unfortun
strategi
limit
rel
immatur
neonat
infant
immun
system
factor
implic
poor
respons
limit
switch
igm
antibodi
impair
complementmedi
reaction
defici
organ
splenic
margin
zone
vaccin
studi
perform
newborn
mice
suggest
limit
germin
centr
reaction
may
result
delay
develop
follicular
dc
limit
plasma
cell
differenti
also
show
neonat
bm
limit
capac
support
establish
longlif
antibodysecret
plasma
cell
thu
respons
glycoconjug
tcelldepend
antigen
usual
affect
therefor
highli
immunogen
vaccin
show
signific
protect
efficaci
singl
dose
infant
limit
igg
respons
extend
first
year
life
addit
immun
respons
particularli
antibodi
elicit
first
year
life
vaccin
rapidli
declin
howev
problem
observ
infant
term
magnitud
durat
immun
respons
seem
affect
effici
prime
fact
immun
memori
gener
neonat
may
recal
later
life
nevertheless
strategi
gener
strong
longlast
protect
respons
infant
still
need
part
due
presenc
matern
antibodi
inactiv
clear
vaccin
antigen
therebi
render
difficult
stimul
immatur
immun
system
addit
effect
adjuv
report
adult
extrapol
neonat
potenti
strategi
overcom
problem
would
implement
vaccin
pregnanc
provid
requir
antibodi
placenta
later
matern
feed
could
complement
earli
prime
immatur
immun
system
newborn
dna
vaccin
follow
boost
second
half
first
year
later
life
polypatholog
multipl
organ
failur
rule
rather
except
age
individu
thu
mani
system
affect
eg
endocrin
cardiovascular
immun
system
except
mechan
involv
immun
senesc
process
turn
may
lead
poor
respons
vaccin
fulli
understood
howev
clear
respons
certain
vaccin
affect
immun
senesc
other
eg
psbase
vaccin
pneumonia
contrast
respons
boost
dose
antitetanu
vaccin
hardli
affect
age
rapid
declin
antibodi
respons
togeth
rel
restrict
tcell
repertoir
characterist
immun
senesc
process
restrict
reduct
pool
cell
explain
poor
cell
respons
antigen
crossreact
protein
seen
earlier
life
contrast
tcell
respons
healthi
elderli
individu
new
antigen
often
unaffect
nevertheless
overal
respons
vaccin
elderli
less
effici
young
adult
make
vigor
approach
necessari
fig
case
influenza
actual
strategi
annual
revaccin
howev
concern
regard
capac
increas
antibodi
proper
specif
reassort
virus
age
adult
repeatedli
infect
immun
exposur
new
crossreact
antigen
variant
individu
may
respond
produc
antibodi
howev
antibodi
could
primarili
direct
influenza
strain
encount
earlier
life
figur
factor
affect
respons
young
adult
age
individu
vaccin
process
immun
senesc
impair
host
respons
infect
vaccin
critic
issu
need
consid
vaccin
design
requir
develop
special
approach
exampl
individu
previous
expos
old
influenza
strain
ie
year
ago
may
respond
differ
adult
vaccin
new
strain
accumul
differ
mutat
former
might
produc
antibodi
ha
old
strain
rather
crossreact
epitop
new
strain
phenomenon
socal
origin
antigen
sin
basi
observ
propos
variat
vaccin
efficaci
might
due
differ
antigen
distanc
vaccin
strain
epidem
strain
respons
influenza
outbreak
howev
hypothesi
confirm
epidemiolog
studi
even
individu
age
year
older
annual
vaccin
show
significantli
reduc
mortal
risk
therefor
seem
antigen
sin
repres
major
practic
obstacl
influenza
vaccin
addit
strategi
may
requir
despit
broad
avail
vaccin
agent
caus
communityacquir
pneumonia
still
repres
import
caus
death
human
suffer
econom
loss
howev
dramat
expand
knowledg
pathophysiolog
diseas
caus
respiratori
pathogen
virul
factor
effector
mechan
respons
clearanc
becom
clearer
microbi
compon
attract
vaccin
target
well
type
immun
respons
need
confer
protect
diseas
thu
possibl
address
vaccin
develop
use
ration
rather
empir
approach
facilit
power
bioinformat
tool
accur
predict
epitop
proteasom
trim
well
avail
broad
palett
immun
modul
deliveri
system
therefor
predict
new
improv
vaccin
etiolog
agent
communityacquir
pneumonia
consider
reduc
global
impact
diseas
come
year
